Prediction and prophylactic treatment of type 1 diabetes

Details Prediction and prophylactic treatment of type 1 diabetes Prediction and prophylactic treatment of type 1 diabetes

2007-07-30

2011-11-22

Weddington, Kevin E (Department: 1629)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S866000

Reexamination Certificate

active

08063011

ABSTRACT:
An in vitro method for predicting the onset of type 1 diabetes (T1 D) in a subject, comprises the steps of: (a) measuring the concentration of at least one amino acid, amino acid derivative or amino acid metabolite in a biological sample taken from the subject; (b) determining the subject's HLA genotype; (c) assigning the subject's genetic risk of developing T1 D on the basis of the subject's HLA genotype; (d) combining the information obtained in step (a) with the information in step (c); and (e) predicting the likelihood of onset of T1 D based upon the combination of step (d). The diagnostic method can be used to select target subjects for T1 D prophylactic treatment, and as part of a T1 D preventative treatment regime for neonates having a likelihood of developing childhood T1 D.

REFERENCES:
patent: 2002/0064549 (2002-05-01), Shehadeh
patent: 2006/0088574 (2006-04-01), Manning et al.
patent: 2008/0026378 (2008-01-01), Bottazzo
patent: 02/13814 (2002-02-01), None
Locatelli et al. (Diabetologia Aug. 2005 vol. 48 p. 114).
WO 2008/035204 A3, International Search Report in International Application No. PCT/IB2007/003024 from which the present application is a U.S. National Stage application.
Locatelli, M. et al. “Children Who Develop Type 1 Diabetes Early in Life Have Low Levels of Carnitine and Amino Acids at Birth: Does This Finding Shed Light on the Etiopathogenesis of the Disease?,” Diabetologia, vol. 48, No. suppl. 1, Aug. 2005, pp. 114-114.
Buzzetti, R., et al. “Genetic Prediction of Type 1 Diabetes in a Population with Low Frequency of HLA Risk Genotypes and Low Incidence of the Disease (the DIABFIN study),” Diabetes/Metabolism Research and Reviews, vol. 20, 2004, pp. 137-143.
Emery, L.M., et al. “Newborn HLA-DR, DQ genotype screening: age- and ethnicity-specific type 1 diabetes risk estimates,” Pediatr Diabetes, vol. 6, No. 3, Sep. 2005, pp. 136-144.
Marks, J.B. “In Pursuit of Type 1 Diabetes Prevention” Clinical Diabetes, vol. 20, No. 4, 2002, pp. 168-169.
Williams, R., et al. “The Evidence Base for Diabetes Care—Part II: Prevention of Diabetes,” 2002.
DeLuca, G. et al. “Preliminary Report: Amino Acid Profile in Platelets of Diabetic Patients,” Metabolism, vol. 50, No. 7, Jul. 2001, pp. 739-741.
Mamoulakis, D. et al. “Carnitine Deficiency in Children and Adolescents with Type 1 Diabetes,” J. of Diabetes and Its Complications, vol. 18, No. 5, Sep. 2004, pp. 271-274.
Devendra et al, “Type 1 diabetes: recent developments,” BMJ Mar. 27, 2004, vol. 328, p. 750.
Wittaker et al., “Whole body protein kinetics in women: effect of pregnancy and IDDM during anabolic stimulation,” American J Physiol Endocrinal Metab, 200 vol. 279 p. E978.
Wijekoon et al., “Amino acid metabolism in the Zucker diabetic fatty rat: effects of insulin resistance and of type 2 diabetes,” Can J. Phyysiol Pharmacol. 2004 vol. 82, p. 506.
Action in related U.S. Appl. No. 11/496,001, dated Mar. 4, 2010.
IPRP in parent PCT application PCT/IB2007/003024.
Written Opinion and ISR in parent PCT application PCT/IB2007/003024.
Co-pending U.S. Appl. No. 11/496,001 to which the present application claims priority, and the file wrapper thereof. Although the application and file wrapper are available to the Office, Applicant submits herewith a courtesy Restriction Requirement and Notice mailed during the prosecution of that matter.
Jay S. Skyler, Prevention of Type 1 Diabetes, The Evidence Base for Diabetes Care, 2002, pp. 44-68, John Wiley & Sons, Ltd.
Akerblom, HK Vaarala O, Hyoty H., Ilonen J., Knip M., “Environmental factors in the etiology of type 1 diabetes.”, (2002), Am J. Med. Genet., May 30; 115(1): 18-29.
Virtanen SM, Knip M., “Nutritional risk predictors of beta cell autoimmunity and type 1 diabetes at a young age.” (2003) Am. J. Clin. Nutr., Dec; 78(6): 1053-67.
Ziegler AG, Schmid S., Huber D., Hummel M., Bonifacio E., “Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies.” (2003) J. Am. Med. Assoc., Oct. 1; 290(13):1721-8.
Redondo MJ, Fain PR, Eisenbarth GS, “Genetics of type 1A diabetes” (2001) Recent Prog. Horm. Res. 56: 69-89.
Ilonen J., Sjoroos M, Knip M, Veijola R, Simell O, Akerblom HK, Paschou P, Bozas E, Havarani B, Malamitsi-Puchner A, Thymelli J, Vazeou A, Bartsocas CS (2002) “Estimation of genetic risk for type 1 diabetes,” Am. J. Med. Genet. 115(1):30-6.
Mimbacas A., Perez-Bravo F, Hidalgo PC, Javiel G, Pisciottano C, Grignola R, Jorge AM, Gallino JP, Gasagoite J, Cardoso H. (2003) “Association between diabetes type 1 and DQB1 alleles in a case-control study conducted in Montevideo, Uruguay,” Genet. Mol. Res. 2(1):29-35.
Lambert AP, Gillespie KM, Thompson G, Cordell HJ, Todd JA, Gale EA, Bingley PJ, “Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom.” (2004) J. Clin. Endocrinol. Metab. 89(8):4037-43.
Buzzetti R, Galgani A, Petrone A, Del Buono MI, Erlich HA, Bugawan TL, Lorini R, Meschi F, Multari G, Pozzilli P, Locatelli M, Bottazzo G, Di Mario U, “Genetic prediction of type 1 diabetes in a population with low frequency of HLA risk genotypes and low incidence of the disease (the DIABFIN study)” (2004), Diabetes Metab. Res. Rev., Mar.-Apr.; 20(2): 137-43.
Galgani A, Petrone A, Spoletini M, Hodge A, Del Buono ML, Locatelli M, Buzzetti R and the Diabfin Study Group. “HLA class II typing in newborns reveals a low frequency of the DRBI*04 allele and a high frequency of DRB1*11 allele in three regions of continental Italy.” (2004) Hum. Immuniol. 65(4): 366-72.

Affiliated with

Also associated with

Rating

Prediction and prophylactic treatment of type 1 diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prediction and prophylactic treatment of type 1 diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prediction and prophylactic treatment of type 1 diabetes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4309908